Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses

Junko Matsuzaki, Takemasa Tsuji, Immanuel F. Luescher, Hiroshi Shiku, Junichi Mineno, Sachiko Okamoto, Lloyd J. Old, Protul Shrikant, Sacha Gnjatic, Kunle Odunsi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Tumor antigen-specific CD4+ T cells generally orchestrate and regulate immune cells to provide immune surveillance against malignancy. However, activation of antigen-specific CD4+ T cells is restricted at local tumor sites where antigen-presenting cells (APCs) are frequently dysfunctional, which can cause rapid exhaustion of anti-tumor immune responses. Herein, we characterize anti-tumor effects of a unique human CD4+ helper T-cell subset that directly recognizes the cytoplasmic tumor antigen, NY-ESO-1, presented by MHC class II on cancer cells. Upon direct recognition of cancer cells, tumor-recognizing CD4+ T cells (TR-CD4) potently induced IFN-γ3-dependent growth arrest in cancer cells. In addition, direct recognition of cancer cells triggers TR-CD4 to provide help to NY-ESO-1-specific CD8+ T cells by enhancing cytotoxic activity, and improving viability and proliferation in the absence of APCs. Notably, the TR-CD4 either alone or in collaboration with CD8+ T cells significantly inhibited tumor growth in vivo in a xenograft model. Finally, retroviral gene-engineering with T cell receptor (TCR) derived from TR-CD4 produced large numbers of functional TR-CD4. These observations provide mechanistic insights into the role of TR-CD4 in tumor immunity, and suggest that approaches to utilize TR-CD4 will augment anti-tumor immune responses for durable therapeutic efficacy in cancer patients.

Original languageEnglish (US)
Article number14896
JournalScientific Reports
Volume5
DOIs
StatePublished - Oct 8 2015

Fingerprint

T-Lymphocyte Subsets
Growth
Neoplasms
T-Lymphocytes
Neoplasm Antigens
Antigen-Presenting Cells
CD4 Antigens
Helper-Inducer T-Lymphocytes
T-Cell Antigen Receptor
Heterografts
Immunity

ASJC Scopus subject areas

  • General

Cite this

Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. / Matsuzaki, Junko; Tsuji, Takemasa; Luescher, Immanuel F.; Shiku, Hiroshi; Mineno, Junichi; Okamoto, Sachiko; Old, Lloyd J.; Shrikant, Protul; Gnjatic, Sacha; Odunsi, Kunle.

In: Scientific Reports, Vol. 5, 14896, 08.10.2015.

Research output: Contribution to journalArticle

Matsuzaki, J, Tsuji, T, Luescher, IF, Shiku, H, Mineno, J, Okamoto, S, Old, LJ, Shrikant, P, Gnjatic, S & Odunsi, K 2015, 'Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses', Scientific Reports, vol. 5, 14896. https://doi.org/10.1038/srep14896
Matsuzaki, Junko ; Tsuji, Takemasa ; Luescher, Immanuel F. ; Shiku, Hiroshi ; Mineno, Junichi ; Okamoto, Sachiko ; Old, Lloyd J. ; Shrikant, Protul ; Gnjatic, Sacha ; Odunsi, Kunle. / Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. In: Scientific Reports. 2015 ; Vol. 5.
@article{6ee57bb8ca8f451291524e1b8ae536db,
title = "Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses",
abstract = "Tumor antigen-specific CD4+ T cells generally orchestrate and regulate immune cells to provide immune surveillance against malignancy. However, activation of antigen-specific CD4+ T cells is restricted at local tumor sites where antigen-presenting cells (APCs) are frequently dysfunctional, which can cause rapid exhaustion of anti-tumor immune responses. Herein, we characterize anti-tumor effects of a unique human CD4+ helper T-cell subset that directly recognizes the cytoplasmic tumor antigen, NY-ESO-1, presented by MHC class II on cancer cells. Upon direct recognition of cancer cells, tumor-recognizing CD4+ T cells (TR-CD4) potently induced IFN-γ3-dependent growth arrest in cancer cells. In addition, direct recognition of cancer cells triggers TR-CD4 to provide help to NY-ESO-1-specific CD8+ T cells by enhancing cytotoxic activity, and improving viability and proliferation in the absence of APCs. Notably, the TR-CD4 either alone or in collaboration with CD8+ T cells significantly inhibited tumor growth in vivo in a xenograft model. Finally, retroviral gene-engineering with T cell receptor (TCR) derived from TR-CD4 produced large numbers of functional TR-CD4. These observations provide mechanistic insights into the role of TR-CD4 in tumor immunity, and suggest that approaches to utilize TR-CD4 will augment anti-tumor immune responses for durable therapeutic efficacy in cancer patients.",
author = "Junko Matsuzaki and Takemasa Tsuji and Luescher, {Immanuel F.} and Hiroshi Shiku and Junichi Mineno and Sachiko Okamoto and Old, {Lloyd J.} and Protul Shrikant and Sacha Gnjatic and Kunle Odunsi",
year = "2015",
month = "10",
day = "8",
doi = "10.1038/srep14896",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses

AU - Matsuzaki, Junko

AU - Tsuji, Takemasa

AU - Luescher, Immanuel F.

AU - Shiku, Hiroshi

AU - Mineno, Junichi

AU - Okamoto, Sachiko

AU - Old, Lloyd J.

AU - Shrikant, Protul

AU - Gnjatic, Sacha

AU - Odunsi, Kunle

PY - 2015/10/8

Y1 - 2015/10/8

N2 - Tumor antigen-specific CD4+ T cells generally orchestrate and regulate immune cells to provide immune surveillance against malignancy. However, activation of antigen-specific CD4+ T cells is restricted at local tumor sites where antigen-presenting cells (APCs) are frequently dysfunctional, which can cause rapid exhaustion of anti-tumor immune responses. Herein, we characterize anti-tumor effects of a unique human CD4+ helper T-cell subset that directly recognizes the cytoplasmic tumor antigen, NY-ESO-1, presented by MHC class II on cancer cells. Upon direct recognition of cancer cells, tumor-recognizing CD4+ T cells (TR-CD4) potently induced IFN-γ3-dependent growth arrest in cancer cells. In addition, direct recognition of cancer cells triggers TR-CD4 to provide help to NY-ESO-1-specific CD8+ T cells by enhancing cytotoxic activity, and improving viability and proliferation in the absence of APCs. Notably, the TR-CD4 either alone or in collaboration with CD8+ T cells significantly inhibited tumor growth in vivo in a xenograft model. Finally, retroviral gene-engineering with T cell receptor (TCR) derived from TR-CD4 produced large numbers of functional TR-CD4. These observations provide mechanistic insights into the role of TR-CD4 in tumor immunity, and suggest that approaches to utilize TR-CD4 will augment anti-tumor immune responses for durable therapeutic efficacy in cancer patients.

AB - Tumor antigen-specific CD4+ T cells generally orchestrate and regulate immune cells to provide immune surveillance against malignancy. However, activation of antigen-specific CD4+ T cells is restricted at local tumor sites where antigen-presenting cells (APCs) are frequently dysfunctional, which can cause rapid exhaustion of anti-tumor immune responses. Herein, we characterize anti-tumor effects of a unique human CD4+ helper T-cell subset that directly recognizes the cytoplasmic tumor antigen, NY-ESO-1, presented by MHC class II on cancer cells. Upon direct recognition of cancer cells, tumor-recognizing CD4+ T cells (TR-CD4) potently induced IFN-γ3-dependent growth arrest in cancer cells. In addition, direct recognition of cancer cells triggers TR-CD4 to provide help to NY-ESO-1-specific CD8+ T cells by enhancing cytotoxic activity, and improving viability and proliferation in the absence of APCs. Notably, the TR-CD4 either alone or in collaboration with CD8+ T cells significantly inhibited tumor growth in vivo in a xenograft model. Finally, retroviral gene-engineering with T cell receptor (TCR) derived from TR-CD4 produced large numbers of functional TR-CD4. These observations provide mechanistic insights into the role of TR-CD4 in tumor immunity, and suggest that approaches to utilize TR-CD4 will augment anti-tumor immune responses for durable therapeutic efficacy in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84943601242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943601242&partnerID=8YFLogxK

U2 - 10.1038/srep14896

DO - 10.1038/srep14896

M3 - Article

AN - SCOPUS:84943601242

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 14896

ER -